Senores Pharmaceuticals Ltd

Senores Pharma. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Senores Pharmaceuticals Ltd

₹ 1,045 1.12%
03 Jun - close price
senorespharma.com BSE: 544319 NSE: SENORES
About

Incorporated in 2015, Senores Pharmaceuticals Ltd manufactures and develops affordable and high-quality complex generics certified by global food and drugs authorities[1]

Key Points

Business Overview:[1]
SPL is a global research-driven pharmaceutical company that develops and manufactures
pharmaceutical products for the Regulated Markets of the US, Canada, and the United Kingdom across various therapeutic areas and dosage forms, with a presence in Emerging Markets. The company develops and manufactures specialty, underpenetrated, and complex pharmaceutical products. It also manufactures critical care injectables and APIs.

Website BSE NSE
  • Market Cap ₹ 4,799 Cr.
  • Current Price ₹ 1,045
  • High / Low ₹ 1,194 / 506
  • Stock P/E 41.6
  • Book Value ₹ 203
  • Dividend Yield 0.00 %
  • ROCE 15.1 %
  • ROE 13.4 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is expected to give good quarter

Cons

  • Stock is trading at 5.16 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 13.9% over last 3 years.
  • Company might be capitalizing the interest cost
  • Company has high debtors of 187 days.
  • Working capital days have increased from 67.9 days to 132 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
79 102 80 101 103 114 138 162 171 175
64 80 59 77 77 95 104 112 121 128
Operating Profit 15 22 21 23 26 19 34 50 50 47
OPM % 19% 22% 27% 23% 25% 17% 25% 31% 29% 27%
1 2 0 2 5 12 3 5 7 18
Interest 2 3 5 5 6 5 5 6 5 8
Depreciation 3 4 4 4 4 5 6 8 8 9
Profit before tax 10 18 13 16 20 21 26 41 45 47
Tax % 31% 19% 19% 18% 20% 13% 20% 26% 25% 23%
7 14 11 13 16 18 21 30 34 37
EPS in Rs 2.37 5.23 3.23 3.86 3.73 3.87 4.28 7.03 6.87 6.86
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
14 35 215 398 633
12 23 173 309 464
Operating Profit 2 13 42 90 168
OPM % 14% 36% 19% 23% 27%
0 4 3 19 47
Interest 1 2 9 22 25
Depreciation 1 2 10 17 31
Profit before tax 1 12 25 71 159
Tax % 13% 32% -31% 17% 24%
1 8 33 58 122
EPS in Rs 1.01 8.59 10.31 12.72 25.05
Dividend Payout % 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 162%
TTM: 59%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 139%
TTM: 97%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 101%
Return on Equity
10 Years: %
5 Years: 14%
3 Years: 14%
Last Year: 13%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 9 10 31 46 46
Reserves 28 36 174 740 888
15 63 258 315 342
8 23 160 126 328
Total Liabilities 59 131 622 1,227 1,604
7 27 235 301 755
CWIP 8 34 97 172 17
Investments 15 16 0 0 4
29 53 289 754 827
Total Assets 59 131 622 1,227 1,604

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
-10 -1 -26 -46 62
-24 -48 -54 -429 -121
36 46 87 573 -1
Net Cash Flow 2 -3 8 98 -60
Free Cash Flow -21 -48 -78 -203 -203
CFO/OP -526% 3% -56% -41% 45%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 506 228 191 114 187
Inventory Days 135 89 184 232 130
Days Payable 324 388 556 275 340
Cash Conversion Cycle 317 -71 -182 70 -24
Working Capital Days 359 -7 -16 88 132
ROCE % 18% 12% 11% 15%

Insights

In beta
Mar 2023 Dec 2024 Dec 2025
Annual Installed Capacity (API Manufacturing)
MTPA

Log in to view insights

Please log in to see hidden values.

Login
Approved ANDA Products/Strengths (Regulated Markets)
Number
Approved ANDAs (Regulated Markets)
Number
Approved Products (Emerging Markets)
Number
CDMO/CMO Commercialized Products
Number
Commercialized ANDAs (Regulated Markets)
Number
Pipeline Products/Applications Filed (Emerging Markets)
Number
Revenue Realization per Unit (Emerging Markets)
INR
Annual Installed Capacity (Atlanta OSD Facility)
Million Units
Annual Installed Capacity (Chhatral General Oral Dosage)
Million Units

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
45.77% 45.78% 45.78% 45.80% 45.81% 45.82%
4.25% 4.17% 3.66% 4.28% 3.35% 3.64%
11.77% 9.66% 9.51% 8.62% 9.32% 9.62%
38.20% 40.39% 41.03% 41.30% 41.54% 40.92%
No. of Shareholders 49,51837,65336,38934,91734,40134,126

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Concalls